The specific mechanisms include ... the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor (sintilimab) and PCSK9 inhibitor (tafolecimab) in the treatment of ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

Though currently experimental, this mechanism could complement existing PD-1 and PD-L1 checkpoint inhibitors and improve patient outcomes. How Checkpoint Inhibitors Work Checkpoint inhibitors are ...

Co-author Dr Kenji Chamoto, from Kyoto University, says, "PD-1 inhibition has a 'yin and yang' nature: it activates anti-tumor immunity but at the same time impedes B-cell immunity.

PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune system to recognize and attack tumors. To get know more ... (Summit Therapeutics) – A new PD-1/PD-L1 ...

We are excited to explore the potential of our PD-1 inhibitor, tislelizumab, in combination with ANKTIVA,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. “I’ve admired Dr.

(NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...

According to Akeso, the HARMONi-6 trial marks ivonescimab’s third Phase III success in lung cancer and its second head-to-head win over a PD-1 inhibitor.1 Currently, the treatment is approved in China ...

Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune ... tumor responses achieved with PD-1/PD-L1 blockade alone.